EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY 4.0

Randomized Phase 1 Studies Evaluating the Safety, Tolerability, Pharmacokinetics, and Target Occupancy of Zampilimab in Healthy Participants

Jo Collier, Rowann Bowcutt, Geoffrey I Johnston, Jane Y C Chan, Anastasiia Raievska, Alison Bigley, Richard Nicholl, Tim S Schmidt, Maria Sarno, Zahid Ali, Elizabeth Thomson

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.70052 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Jo Collier und 10 weiteren Autor:innen. Beteiligte Einrichtung: UCB, Slough, UK. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Transglutaminases, GTP-Binding Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funded by UCB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zampilimab (UCB7858) is a humanized monoclonal immunoglobulin G4P, transglutaminase 2 (TG2) inhibiting antibody. We investigated safety, tolerability, pharmacokinetics, and target occupancy of zampilimab (intravenous ≤2000 mg; subcutaneous ≤1000 mg) in healthy participants in a randomized, placebo‑controlled, single‐ascending‐dose Phase 1 study (UP0029; NCT02879877). Of 78 participants (58 zampilimab; 20 placebo), treatment‐emergent adverse events (TEAEs) occurred in 42 (72.4%) versus 14 (70%), respectively. One participant (intravenous zampilimab 2000 mg) reported a serious TEAE of moderate infusion‐related reaction (a protocol‐defined stopping criterion), leading to a temporary study hold. Although the reaction resolved within 3 days, and the participant completed follow up, dose‐escalation was suspended, and the study terminated. Zampilimab demonstrated dose‐proportional, linear pharmacokinetics (t 1/2 17‐23 days; subcutaneous bioavailability 77%). TG2 target occupancy in skin directly correlated with serum zampilimab concentration, near‐maximal occupancy ≥250 µg/mL, corresponding to intravenous doses ≥1000 mg between Days 2 and 5. A subsequent randomized, placebo‑controlled, Phase 1 study (UP0105; NCT04705350) investigated single intravenous doses of zampilimab (2000 and 3000 mg) at a lower concentration and slower infusion rate versus UP0029, using learnings from the administration strategy. Of 16 participants (12 zampilimab; four placebo), TEAEs occurred in eight (66.7%) versus one (25%), respectively. TEAEs were mild/moderate; none were drug related. No infusion‐related reactions occurred. Zampilimab safety profile was acceptable after single intravenous and subcutaneous doses ≤1000 mg (UP0029) and intravenous doses ≤3000 mg (UP0105) following optimization of maximum concentration (10 mg/mL) at an infusion rate of 25 mg/min over 120 min. These studies support the ongoing development of zampilimab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedTransglutaminasesGTP-Binding ProteinsHumansMaleAdultFemaleYoung AdultMiddle AgedDose-Response Relationship, DrugDouble-Blind MethodHealthy VolunteersProtein Glutamine gamma Glutamyltransferase 2Infusions, IntravenousInjections, SubcutaneousBiological AvailabilityAdolescent

Stichwörter der Autor:innen

TG2drug safetyfibrosisfirst‐in‐human Phase 1 studynephrologypharmacoepidemiologytarget occupancyzampilimab

Substanzen

Antibodies, Monoclonal, HumanizedProtein Glutamine gamma Glutamyltransferase 2TransglutaminasesGTP-Binding Proteins

Autor:innen und Institutionen

  • UCB, Slough, UK.
  • Veramed, London, UK.
  • OracleBio, Biocity, Scotland, UK.

Förderung

  • Funded by UCB

Zitieren

APA

Collier, J., Bowcutt, R., Johnston, G. I., Chan, J. Y. C., Raievska, A., Bigley, A., Nicholl, R., Schmidt, T. S., Sarno, M., Ali, Z., & Thomson, E. (2026). Randomized Phase 1 Studies Evaluating the Safety, Tolerability, Pharmacokinetics, and Target Occupancy of Zampilimab in Healthy Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70052

Vancouver

Collier J, Bowcutt R, Johnston GI, Chan JYC, Raievska A, Bigley A, et al. Randomized Phase 1 Studies Evaluating the Safety, Tolerability, Pharmacokinetics, and Target Occupancy of Zampilimab in Healthy Participants. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70052

BibTeX
@article{Collier2026,
  author = {Collier, Jo and Bowcutt, Rowann and Johnston, Geoffrey I and Chan, Jane Y C and Raievska, Anastasiia and Bigley, Alison and Nicholl, Richard and Schmidt, Tim S and Sarno, Maria and Ali, Zahid and Thomson, Elizabeth},
  title = {Randomized Phase 1 Studies Evaluating the Safety, Tolerability, Pharmacokinetics, and Target Occupancy of Zampilimab in Healthy Participants},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.70052}
}
Kostenlos starten →